Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 1/20 | 0.64 |
| ▸ | TOP2A | P11388 | 1/20 | 0.55 |
| ▸ | MAOA | P21397 | 4/20 | 0.50 |
| ▸ | MAOB | P27338 | 4/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.46 |
| ▸ | GABRP | O00591 | 1/20 | 0.45 |
| ▸ | GABRD | O14764 | 1/20 | 0.45 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.45 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.45 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.45 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.45 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.45 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.45 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.45 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29358773 | 1.00 | GPR3 (0.64) | GPR3TOP2AMAOAMAOBCYP11B2 | |
| SCHEMBL30929605 | 1.00 | GPR3 (0.64) | GPR3TOP2AMAOAMAOBCYP11B2 | |
| SCHEMBL18381764 | 0.98 | GPR3 (0.61) | GPR3TOP2AMAOAMAOBCYP11B2 | |
| Hydrochloric Acid SCHEMBL3333705 | 0.98 | GPR3 (0.61) | GPR3TOP2AMAOAMAOBCYP11B2 | |
| SCHEMBL18381814 | 0.91 | MAOA (0.54) | GPR3TOP2AMAOAMAOBCYP11B2 | |
| SCHEMBL18381778 | 0.90 | GPR3 (0.61) | GPR3TOP2AMAOAMAOBCYP11B2 | |
| SCHEMBL18381818 | 0.90 | GPR3 (0.61) | GPR3TOP2AMAOAMAOBCYP11B2 | |
| SCHEMBL1609661 | 0.89 | ADORA3 (0.54) | GPR3TOP2AMAOAMAOBACHE | |
| SCHEMBL29548306 | 0.88 | GPR3 (0.64) | GPR3TOP2AMAOAMAOBCYP11B2 | |
| SCHEMBL280028 | 0.88 | GPR3 (0.64) | GPR3TOP2AMAOAMAOBCYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 324 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9107914-B2 | Beta-carbolines for use in the treatment of hearing loss and vertigo | AUDIOCURE PHARMA GMBH (DE) | 2015-08-18 | — | — | US | claimed |
| EP-2519238-B1 | BETA-CARBOLINES FOR THE TREATMENT OF HEARING LOSS AND VERTIGO | AUDIOCURE PHARMA GMBH (DE) | 2014-08-13 | — | — | EP | claimed |
| EP-2635575-A1 | CARBAZOLE AND CARBOLINE DERIVATIVES, AND PREPARATION AND THERAPEUTIC APPLICATIONS THEREOF | Philip Morris Products S.a.s. (CH) | 2013-09-11 | — | — | EP | claimed |
| US-20130028958-A1 | BETA-CARBOLINES FOR USE IN THE TREATMENT OF HEARING LOSS AND VERTIGO | AUDIOCURE PHARMA GMBH (DE) | 2013-01-31 | — | — | US | claimed |
| CN-102844029-A | Beta-carbolines for use in the treatment of hearing loss and vertigo | AUDIOCURE PHARMA GMBH | 2012-12-26 | — | — | CN | claimed |
| US-8334299-B2 | β-carboline for the treatment of neurodegenerative diseases | ELLNEUROXX, LTD. (DE) | 2012-12-18 | — | — | US | claimed |
| WO-2012059232-A1 | CARBAZOLE AND CARBOLINE DERIVATIVES, AND PREPARATION AND THERAPEUTIC APPLICATIONS THEREOF | PHILIP MORRIS PRODUCTS S.A (CH) | 2012-05-10 | — | — | WO | claimed |
| US-20100143474-A1 | B-CARBOLINE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | ELLNEUROXX, LTD. | 2010-06-10 | — | — | US | claimed |
| US-20090227619-A1 | Harmine derivatives, intermediates used in their preparations, preparation processes and use therefo | XINJIANG HUASHIDAN PHARMACEUTICAL RESEARCH CO., LTD. (CN) | 2009-09-10 | — | — | US | claimed |
| US-12048238-B2 | Organometallic compound and organic light-emitting device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2024-07-23 | — | — | US | disclosed |
| US-20240244870-A1 | LIGHT-EMITTING DEVICE, ELECTRONIC DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2024-07-18 | — | — | US | disclosed |
| US-20240244952-A1 | ORGANIC LIGHT-EMITTING DEVICE AND ORGANOMETALLIC COMPOUND | SAMSUNG DISPLAY CO., LTD. (KR) | 2024-07-18 | — | — | US | disclosed |
| WO-2024118767-A2 | TRYPTAMINE DERIVATIVES | CAAMTECH, INC. (US) | 2024-06-06 | — | — | WO | disclosed |
| WO-2024100120-A1 | REDUCTION OR PREVENTION OF A MALARIA PARASITE OR DENGUE VIRUS TRANSMISSION WITH 1 -METHYL-9H-PYRIDO[3,4-B]INDOLE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-05-16 | — | — | WO | disclosed |
| US-20070009760-A1 | Coordination metal compound, material for organic electroluminescence device, material for luminescent coating formation and organic electroluminescence device | INOUE TETSUYA | 2007-01-11 | — | — | US | disclosed |
| WO-2006124003-A1 | COMPOSITE MALDI MATRIX MATERIAL AND METHODS OF USING IT AND KITS THEREOF IN MALDI | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2006-11-23 | — | — | WO | disclosed |
| EP-1634881-A1 | HARMINE DERIVATIVES, INTERMEDIATES USED IN THEIR PREPARATION, PREPARATION PROCESSES AND USE THEREOF | Xinjiang Huashidan Pharmaceutical Research Co., Ltd. (CN) | 2006-03-15 | — | — | EP | disclosed |
| EP-0985674-B1 | ORGANIC COMPOUNDS CONTAINING SILICON OR GERMANIUM, TRANSITION METAL COMPLEXES, CATALYST FOR ALPHA-OLEFIN POLYMERIZATION, AND PROCESSES FOR PRODUCING ALPHA-OLEFIN POLYMERS | MITSUBISHI CHEM CORP (JP) | 2003-04-23 | — | — | EP | disclosed |
| US-6255515-B1 | COORDINATION POLYMERIZATION CATALYSTS | MITSUBISHI CHEMICAL CORPORATION (JP) | 2001-07-03 | — | — | US | disclosed |
| EP-0985674-A1 | ORGANIC COMPOUNDS CONTAINING SILICON OR GERMANIUM, TRANSITION METAL COMPLEXES, CATALYST FOR $g(a)-OLEFIN POLYMERIZATION, AND PROCESSES FOR PRODUCING $g(a)-OLEFIN POLYMERS | MITSUBISHI CHEMICAL CORPORATION (JP) | 2000-03-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130028958-A1 | BETA-CARBOLINES FOR USE IN THE TREATMENT OF HEARING LOSS AND VERTIGO | CBFB, ADRA2B, SLC6A12 | GPR3 930/4885TOP2A 584/4885MAOA 2170/4885 |
| US-20240244952-A1 | ORGANIC LIGHT-EMITTING DEVICE AND ORGANOMETALLIC COMPOUND | LEF1, OCIAD1, OXA1L | GPR3 3844/4885TOP2A 3641/4885MAOA 799/4885 |
| US-12048238-B2 | Organometallic compound and organic light-emitting device including the same | TRPC1, PPOX, LAGE3 | GPR3 2696/4885TOP2A 3689/4885MAOA 3176/4885 |
| US-20100143474-A1 | B-CARBOLINE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | PARK7, SNCA, CHAT | GPR3 208/4885TOP2A 1995/4885MAOA 130/4885 |
| US-20090227619-A1 | Harmine derivatives, intermediates used in their preparations, preparation processes and use therefo | TPH1, HTR1F, TPH2 | GPR3 1650/4885TOP2A 315/4885MAOA 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.